Advanced Search:
Equity Index Forex Crypto Commodity

EXEL - Exelixis

$23.70  0.17 (0.72%)

Updated: 01:09 Apr 28, 2024 EST

Next Hour's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Session's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Week's AI Forecast

N/A

Trend's Accuracy (AI)

N/A

Exelixis's Position Within the Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

EXELIXIS - HISTORICAL DATA 6M

  • Last price

    $ 23.70

  • Daily change

    $ 0.17

  • Previous Close

    $ 23.53

  • Last Updated

    01:09 Apr 28, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 -0.01 0.3 0.1 0.09

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 1.17 1.08 1.17 1.22

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
N/A N/A 99.18% 94.04%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0 -100% 23.42 0.39% 23.33 5.04% 22.21

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
1.29 60.32 1.25 56.33

Exelixis Technical Analysis News

Exelixis

1851 Harbor Bay Parkway
Alameda, CA 94502
United States
650 837 7000
https://www.exelixis.com

Description

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Corporate Governance

Exelixis, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 3. The pillar scores are Audit: 4; Board: 3; Shareholder Rights: 4; Compensation: 4.

EXELIXIS'S HOLDERS RANK

List of holders with stock participation in Exelixis.

Holder Rank Holder Shares Date Reported % Out Value